Ruxolitinib for the treatment of graft-versus-host disease.

Expert Review of Clinical Immunology
Haris AliRyotaro Nakamura

Abstract

Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD. Early clinical observations that ruxolitinib was effective in treatment of steroid-refractory (SR) acute and chronic GVHD led to the development of prospective clinical trials; Phase II REACH1 (NCT02953678), Phase III REACH2 (NCT02913261), and REACH3 (NCT03112603). Based on the data from the REACH1 trial, ruxolitinib was approved by the FDA in May 2019 for SR acute GVHD in adult and pediatric patients 12 years and older.Expert opinion: Ruxolitinib and other JAK1/JAK2 inhibitors hold promise in other treatment settings such as GVHD prevention and/or first-line therapy.

References

Aug 1, 1991·The New England Journal of Medicine·K I Kaitin
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·S E NicholsonJ E Layton
Apr 16, 2002·Science·Polly Matzinger
Mar 23, 2005·Lancet·E Joanna BaxterUNKNOWN Cancer Genome Project
Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Sep 10, 2005·Bone Marrow Transplantation·A GratwohlUNKNOWN Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Jan 20, 2007·Blood·H Joachim Deeg
Mar 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kevin SheKirk R Schultz
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
Jun 15, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John E LevineUNKNOWN Blood and Marrow Transplant Clinical Trials Network
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Apr 19, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul J MartinPaul A Carpenter
Apr 27, 2012·British Journal of Haematology·Fiona L DignanUNKNOWN British Society for Blood and Marrow Transplantation
Jul 10, 2012·Nature Medicine·Thomas A Wynn, Thirumalai R Ramalingam
Sep 14, 2012·Blood·Jaebok ChoiJohn F DiPersio
Dec 10, 2013·Therapeutic Advances in Hematology·Catherine GarnettJiří Pavlů
Apr 9, 2014·Blood·Silvia SpoerlNikolas von Bubnoff
Jun 14, 2014·Blood·Takanori Teshima
Dec 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Madan H JagasiaMary E D Flowers
Apr 23, 2015·The New England Journal of Medicine·Alessandro M Vannucchi
Apr 23, 2015·The New England Journal of Medicine·Hans C Hasselbalch, Mads E Bjørn
Dec 4, 2015·Nature Reviews. Rheumatology·Daniella M SchwartzJohn J O'Shea
Mar 29, 2016·British Journal of Haematology·John MagenauPavan Reddy
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Aug 10, 2016·Journal of Hematology & Oncology·Enrico MaffiniBenedetto Bruno
Oct 11, 2016·Bone Marrow Transplantation·Y MoriT Teshima
Mar 28, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pooja KhandelwalKasiani C Myers
Jun 24, 2017·Cell Communication and Signaling : CCS·Farhad SeifMohammadali Bahar
Dec 28, 2017·The New England Journal of Medicine·Robert Zeiser, Bruce R Blazar
Jan 1, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mark A SchroederJohn F DiPersio
Jan 26, 2018·Bone Marrow Transplantation·Hanna Jean KhouryJohn F DiPersio

❮ Previous
Next ❯

Citations

Dec 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Karima AlimOlivier Fardel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.